Key Takeaways Incyte rose 5.1% after partnering with QIAGEN to advance diagnostics for rare blood cancers. QIAGEN will create a next-generation sequencing panel focused on mutCALR for MPNs patient selection. Early data shows INCY's INCA033989 yields strong responses and targets mutCALR while sparing healthy cells.Shares of Incyte (INCY) gained 5.1% on Monday following the announcement of a global partnership with Netherlands-based QIAGEN N.V. (QGEN) . The collaboration aims to develop a novel diagnostic p ...